- cafead Feb 28, 2021 at 10:12: PM
via Gossamer Bio has been unraveling over the past year, hit hard by a failure for its leading drug program and the axing of its CEO Sheila Gujrathi, M.D., soon after.
The failure that rocked the company last October was for GB001, an oral DP2 antagonist for eosinophilic asthma. The promise of DP2 inhibition has attracted some Big Pharma names over the years, yet none of those heavyweight drug developers were able to build on evidence that activation of the prostaglandin receptor drives allergy and inflammation and go on to create efficacious therapies.
article source
The failure that rocked the company last October was for GB001, an oral DP2 antagonist for eosinophilic asthma. The promise of DP2 inhibition has attracted some Big Pharma names over the years, yet none of those heavyweight drug developers were able to build on evidence that activation of the prostaglandin receptor drives allergy and inflammation and go on to create efficacious therapies.
article source